Next Up?
So, the natural expectation now that Medtronic has backed out of their deal to buy EOFlow is who’s next up. Medtronic foolishly wants to be in the patch pump business, when they really should be getting out of diabetes, so who’s next. Why not Embecta as they have a way cool whiz bang patch pump for Type 2 patients. Or what about our friends here in San Diego Modular Medical....
Another one bites the dust.
In a move that should not surprise readers as we predicted it Medtronic killed their deal to acquire EOFlow and in the process likely pushed EOFlow into bankruptcy as Medtronic is NOT paying a termination fee. Here is the exact wording from the 8K Medtronic filed yesterday. “On May 25, 2023, Medtronic plc (Medtronic) announced that it had entered into a set of definitive agreements (Agreements) to acquire EOFlow Co. Ltd....
What really matters.
This morning Tandem announced that the t: slim X2 now works with Dexcom G7 sensor. This really isn’t big news as Insulet will soon have the Omnipod working with the G7 as will Beta Bionics have the iLet. What really is news here is the absence of any news on any of these systems working with any version of the Libre. A. system which has an iCGM designation which it...
The reason why!
Yesterday I noted that the iLet by Beta Bionics has the opportunity to hurt both Tandem and Medtronic. The biggest reason isn’t because the iLet is easy to use no the biggest reason is Beta Bionics has done what Tandem and Medtronic have been unable or incapable of doing, the iLet will be available through the pharmacy channel and will not have to compete with the 780G or Control IQ...
A Couple of Turkeys
Listen we know everyone is getting ready for the Thanksgiving holiday but there are a few items to comment on before we chow down on Turkey and watch the Lions beat the Packers. (You realize as a Bears fan we must root for any team that plays the Packers and this year the Lions are pretty damn good.) Ok we’ll get plenty of football over the next few days so...
Super Fight II
Before we get into things today some shameless self-promotion for my special report The Ozempic Effect The Hype The Hysteria The Truth which is about to be published and in hot demand. Just a reminder that as a subscriber you get a 10% discount and can order this great report by contacting me directly at dkliff@diabeticinvestor.com. Now onto business Not sure how many remember the three major title fights between Muhammad Ali...
Bell Ringing
Yesterday morning Dexcom CEO Kevin Sayer rang the opening bell for the Nasdaq later that afternoon Insulet CEO Jim Hollingshead rang the closing bell. Noticeably absent from the podium was Tandem CEO John Sheridan. While Mr. Sayer and Mr. Hollingshead are being cheered by their stakeholders Mr. Sheridan is lucky, he’s not being whacked by Tandem stakeholders. Since taking over as CEO on March 1, 2019, Tandem shares have fallen over...
Talent wins again!
Yes, today is World Diabetes Day which occurs in November which is a month devoted to diabetes. Supposedly the goal of these marketing designed events is to raise awareness. Given that diabetes continues to grow at epidemic rates, that still after the billions spent nearly two thirds of patients are NOT achieving good control it’s difficult to see why we need more awareness. Let’s be honest here folks you can’t...
The Future Will Look Like The Past
Not a day goes by without someone asking me who the third player will be in the CGM market. It won’t be Senseonics nor will be it be Medtronic the two companies besides Dexcom and Abbott to have an FDA approved sensor. Implantable is a bad business model and Medtronic is clueless. And let’s state up front we do not care who has a CE mark it’s FDA approval that...
Who benefits most?
Before we begin today a little shameless self-promotion. My special report The Ozempic Effect The Hype The Hysteria The Truth is shaping up as a best seller. This deep dive into how Ozempic Wegovy Mounjaro will impact not just our wacky world but the world in general is going to be a fascinating read. As with most things we write it will contain actionable information and of course will be...